Table 3.
ID | HPV16 DNA Detection in Oral Rinses |
Smoking Status |
T Stage |
N Stage |
Primary Treatment |
Clinical Follow-up After Diagnosis, mo |
Site of Recurrence |
Salvage Treatment |
Time From First HPV16-Positive Posttreatment Oral Rinse to Recurrence, mo |
Vital Status at Last Follow-up |
---|---|---|---|---|---|---|---|---|---|---|
1 | Persistent | Never | T2 | N2b | CRT | 24.2 | Local, regional, distant | CT | 10.9 | AWD |
2 | Persistent | Former | T4 | N2c | CRT | 20.0 | Regional, distant | CT | NAa | DOD |
3 | Persistent | Never | T2 | N2c | CRT | 36.8 | Local | Surgery + RT | 6.9 | NED |
4 | Persistent | Never | T3 | N2c | CRT | 34.6 | Local, regional | Surgery, then CT, then palliative RT | 3.7 | DOD |
5 | Persistent | Current | T2 | N2b | Surgery + RT | 36.2 | Distant | CT | 7.0 | DOD |
6 | New after treatment | Never | T3 | N2c | CRT | 23.0 | NAb | NAb | NAb | NED |
Abbreviations: AWD, alive with disease; CT, chemotherapy; CRT, chemoradiotherapy; DOD, died of disease; NA, not applicable; NED, no evidence of disease; RT, radiation therapy.
First posttreatment oral rinse obtained after diagnosis of recurrence.
Patient 6 did not have disease recurrence during the study period.